Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 92 results for "sarabjit kour nangra"

Higher growth will bring the attrition rate down for Infosys: Sarabjit Kour Nangra
Business Standard

Higher growth will bring the attrition rate down for Infosys: ...

Interview with Sarabjit Kour Nangra, VP Research - IT, Angel Broking Faraan Tarique | Mumbai January 9, 2015 Last Updated at 16:00 IST Analysts are quite impressed by third-quarter results from Infosys as it turned out to be better than what they had ... Business Standard, 2 months ago

1 images for "sarabjit kour nangra"

Business Standard, 2 months ago
Calcutta Telegraph

Sun-Ranbaxy integration: Entity to corner 9% of desi market

MUMBAI: Following the successful closure of the $3.2 billion merger with troubled drug maker Ranbaxy, Dilip Shanghvi-led Sun Pharma said on Wednesday that the company is initiating the integration of the business, which will make the combined entity ...
 Times of India1 day ago Ranbaxy suffers fresh jolt  Calcutta Telegraph1 month ago Ranbaxy loses generic exclusivity over $6 billion Nexium market  DNA India1 month ago Ranbaxy loses US generic exclusivity over $6 bn Nexium [DNA : Daily News & Analysis (India)]  Pharmacy Choice1 month ago
Livemint.com

Sun Pharma completes Ranbaxy deal

Shares of Sun Pharma rose as much as 2.4% in intra-day trade on Wednesday, while those of Ranbaxy jumped 2.1%. Photo: Hemant Mishra/Mint Mumbai: Sun Pharmaceutical Industries Ltd, India's most valuable drug maker, has completed the $3.2 billion ...
 Livemint.com1 day ago Ranbaxy-Sun Pharma merger to create world's fifth-largest generic drug firm  Business Today India1 day ago

Ipca Lab gets import alert from USFDA: What experts say

The USFDA has imposed import alerts on Silvassa and Indore (formulation facilities for US) for IPCA. However, Hydroxychloroquine Sulfate and Propanolol Hydrochloride, which accounted for around 45% of its total US sales in FY2014, are exempted from ...
 MyIris1 day ago Should investors buy Ipca Labs after sharp fall?  Economic Times2 days ago IPCA Labs tanks 9%, gets USFDA import alert for Ratlam unit  Moneycontrol.com2 months ago IPCA shares down on USFDA import alert  Hindu Business Line2 months ago
Rediff.com

Sensex marks lowest close in 10 weeks; power trips, IT, auto up

The 30-share Sensex ended 50 points lower at 28,112 and the 50-share Nifty declined 12 points to close at 8,531. Markets ended lower for the sixth straight session, amid volatile trades, as traders turned cautious and booked profits ahead of the March F&O expiry tomorrow.    A sharp decline among the infrastructure, metals & mining and oil & gas stocks was evident on the bourses after the Standard & Poor's (S&P) Ratings Services suggested that Indian companies in ...
 Rediff.com1 day ago

Nifty holds 8,500 ahead of March F&O expiry

Markets ended lower amid choppy trades as investors turned cautious and resorted to profit-booking ahead of the March F&O expiry which is due tomorrow. A sharp decline among the infrastructure, metals & mining and oil & gas stocks was evident ...
 Business Standard India2 days ago Sensex ends 118 points lower amid choppy trades  Business Standard India2 days ago

Markets remain flat; pharma shares gain

Markets are trading flat with a negative bias in the late noon trades as investors turn cautious and resorted to profit-booking ahead of the March F&O expiry which is due tomorrow. selling pressure in capital goods, metal, real estate and power ...
 Smart Investor2 days ago

Lupin hits new high on USFDA nod for anti-inflammatory drug

Shares of Lupin touched a record high of Rs 1,958 on Thursday, up 4.5 percent intraday. The US subsidiary received approval from US Food and Drug Administration (USFDA) for anti-inflammatory drug Celecoxib (Celebrex). The company has been selling ...
 Moneycontrol.com1 week ago Lupin Stock Gains on Pain Killer Drug Approval  NDTV Profit1 week ago

Season of muted growth

The fourth quarter of the financial year is expected to be ‘soft’ for the IT industry with muted revenue growth. Cross-currency fluctuations have played a major part in the projections and companies — including TCS, Wipro and Mindtree — are expecting ...
 The Financial Chronicle1 week ago

Wipro bullish in near term

At a time when IT exporters have voiced growth concerns, Wipro has maintained its guidance and is bullish about its prospects for the upcoming financial year. However, Wipro believes that some sectors are witnessing pullback in terms of capex and ...
 Hindu Business Line1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less